Drug Index


Mechanism :

Pimecrolimus binds to the intracellular protein FKBP-12, inhibiting calcineurin, which blocks cytokine transcription and inhibits T-cell activation.

Indication :

  • Atopic dermatitis: Second-line therapy for short-term and non-continuous long-term treatment of mild to moderate atopic dermatitis in immunocompetent patients 2 years and older.
  • Off-label: Intertriginous and facial psoriasis; Oral lichen planus; Vitiligo.

Contraindications :

Hypersensitivity to pimecrolimus or any component of the formulation.

Dosing :

≥2 years:
Apply cream (1%) thin layer to affected area twice daily.

Adverse Effect :

Headache, fever, influenza, local burning, nasopharyngitis, bronchitis, folliculitis, acne vulgaris, impetigo, warts, hypersensitivity, sore throat, asthma.

Interaction :

CYP3A4 Inhibitors: May decrease the metabolism of Pimecrolimus.
Immunosuppressants: Pimecrolimus may enhance the adverse/toxic effect of Immunosuppressants.

Hepatic Dose :

No dose adjustment recommended.
12/17/2023 21:59:11 Pimecrolimus
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0